Staidson BioPharm(SZ:300204) Xin Lang Cai Jing·2025-09-12 06:30Group 1 - The core point of the news is the performance and market position of Shutaishen (Beijing) Biopharmaceutical Co., Ltd., which saw a stock price increase of 5.06% to 41.71 CNY per share, with a trading volume of 1.532 billion CNY and a turnover rate of 8.45%, resulting in a total market capitalization of 19.928 billion CNY [1] - Shutaishen's main business involves the research, production, and sales of biological products and some chemical drugs, with the revenue composition being 59.17% from injectable mouse nerve growth factor (Sutai) and 33.19% from compound polyethylene glycol electrolyte powder [1] Group 2 - From the perspective of fund holdings, Changcheng Fund has a significant position in Shutaishen, with the Changcheng Health Life Mixed A Fund holding 328,900 shares, accounting for 3.57% of the fund's net value, making it the eighth largest holding [2] - The Changcheng Health Life Mixed A Fund has achieved a year-to-date return of 40.81% and a one-year return of 60.77%, ranking 1386 out of 8174 and 2045 out of 7981 in its category, respectively [2] Group 3 - The fund manager of Changcheng Health Life Mixed A is Tan Xiaobing, who has a tenure of 9 years and 225 days, with the fund's total asset size being 2.967 billion CNY [3] - During Tan's tenure, the best fund return was 176.09%, while the worst return was a loss of 28.66% [3]